EU regulators back Novartis inhaler, Gilead HIV drug
LONDON, July 26
LONDON, July 26 (Reuters) - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Investigators look for motive in Malaysia plane disappearance |
- Police make third arrest in murder of Colorado socialite
- Malaysian PM says lost airliner was diverted deliberately |
- Malaysia PM says lost plane's movements indicate a deliberate act
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources